Protein could lead to better TB vaccine

The current vaccine for tuberculosis uses a bovine version of the disease to protect humans who've contracted the illness. It provides some protection but is not entirely effective. However, researchers from the National Heart and Lung Institute at Imperial College London say they've identified a protein that elicits a stronger immune response in those with TB. The protein, called EspC, could be used to provide more better immunity than the currently available vaccine. Report

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.